These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1673 related items for PubMed ID: 24718959

  • 1. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [Abstract] [Full Text] [Related]

  • 2. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [Abstract] [Full Text] [Related]

  • 3. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.
    Cochrane Database Syst Rev; 2015 Apr 18; 2015(4):CD005468. PubMed ID: 25887212
    [Abstract] [Full Text] [Related]

  • 4. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
    Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S.
    Health Technol Assess; 2016 Feb 18; 20(9):1-334, v-vi. PubMed ID: 26847392
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J.
    Ann Rheum Dis; 2014 Jan 18; 73(1):39-47. PubMed ID: 24013647
    [Abstract] [Full Text] [Related]

  • 6. Certolizumab pegol in axial spondyloarthritis.
    Song IH, Rudwaleit M.
    Expert Rev Clin Immunol; 2013 Dec 18; 9(12):1161-72. PubMed ID: 24215406
    [Abstract] [Full Text] [Related]

  • 7. Biologic therapies for spondyloarthritis: what is new?
    Baraliakos X, Braun J.
    Curr Rheumatol Rep; 2012 Oct 18; 14(5):422-7. PubMed ID: 22855297
    [Abstract] [Full Text] [Related]

  • 8. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK, Kapetanovic MC, Petersson IF, Geborek P, Kristensen LE.
    Arthritis Res Ther; 2015 Dec 24; 17():378. PubMed ID: 26703005
    [Abstract] [Full Text] [Related]

  • 9. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.
    Rheumatology (Oxford); 2017 Sep 01; 56(9):1498-1509. PubMed ID: 28498975
    [Abstract] [Full Text] [Related]

  • 10. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
    Machado MA, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EI, Cherchiglia ML, Acurcio Fde A.
    Rheumatol Int; 2013 Sep 01; 33(9):2199-213. PubMed ID: 23686218
    [Abstract] [Full Text] [Related]

  • 11. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial.
    Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, Lange E, Freundlich B, Rudwaleit M, Sieper J.
    Ann Rheum Dis; 2013 Jun 01; 72(6):823-5. PubMed ID: 23172749
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M, Wood E, Combe B, Schaeverbeke T, Miceli-Richard C, Berenbaum F, Koppiker N, Dubanchet A, Logeart I.
    Arthritis Res Ther; 2014 Nov 27; 16(6):481. PubMed ID: 25428762
    [Abstract] [Full Text] [Related]

  • 13. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
    Lubrano E, Perrotta FM, Marchesoni A, D'Angelo S, Ramonda R, Addimanda O, Olivieri I, Punzi L, Salvarani C.
    J Rheumatol; 2015 Feb 27; 42(2):258-63. PubMed ID: 25512483
    [Abstract] [Full Text] [Related]

  • 14. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D.
    Cochrane Database Syst Rev; 2015 Jul 17; 2015(7):CD010952. PubMed ID: 26186173
    [Abstract] [Full Text] [Related]

  • 15. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.
    PLoS One; 2012 Jul 17; 7(1):e30275. PubMed ID: 22272322
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.
    Ren L, Li J, Luo R, Tang R, Zhu S, Wan L.
    Am J Med Sci; 2013 Dec 17; 346(6):455-61. PubMed ID: 23715113
    [Abstract] [Full Text] [Related]

  • 17. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S, He Q, Shuai Z.
    Clin Rheumatol; 2018 Feb 17; 37(2):439-450. PubMed ID: 29290076
    [Abstract] [Full Text] [Related]

  • 18. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
    Ciurea A, Scherer A, Weber U, Exer P, Bernhard J, Tamborrini G, Riek M, Müller RB, Weiss B, Nissen MJ, Kissling R, Michel BA, Finckh A, Rheumatologists of Swiss Clinical Quality Management Program for Axial Spondyloarthritis.
    Ann Rheum Dis; 2016 Mar 17; 75(3):532-9. PubMed ID: 25667205
    [Abstract] [Full Text] [Related]

  • 19. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.
    J Med Econ; 2012 Mar 17; 15(6):1054-63. PubMed ID: 22563743
    [Abstract] [Full Text] [Related]

  • 20. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 17; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 84.